Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [0.03%]
一种偏向性的GLP-1受体激动剂艾司那肽对超重或肥胖成人患者的有效性和安全性：一项多中心、随机、双盲、安慰剂对照的III期临床试验
Linong Ji,Leili Gao,Haibo Xue et al.
Linong Ji et al.
Background: Ecnoglutide is a novel cyclic adenosine monophosphate (cAMP)-biased GLP-1 receptor agonist currently in development for weight management. We aimed to assess the efficacy and safety of once weekly ecnoglutide ...
Charlotte K Boughton
Charlotte K Boughton
Efficacy and safety of automated insulin delivery in children aged 2-6 years (LENNY): an open-label, multicentre, randomised, crossover trial [0.03%]
5岁以内儿童闭环胰岛素治疗的疗效和安全性（LENNY研究）：一项开放标签、多中心、随机交叉试验
Tadej Battelino,Salla Kuusela,Ambika Shetty et al.
Tadej Battelino et al.
Background: Early-life glycaemic control disturbances can negatively affect brain development and plasticity. This study aimed to assess the efficacy and safety of automated insulin delivery (AID) with the MiniMed 780G sy...
Type 2 diabetes, prediabetes, and MASLD: who and when to screen and how to treat? [0.03%]
2型糖尿病、糖尿病前期和MASLD：如何筛查及治疗？
Christopher D Byrne,Giovanni Targher,Ryan M Buchanan
Christopher D Byrne
Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches [0.03%]
从患者角度重新评估2型糖尿病缓解的概念
Kamlesh Khunti,Dimitris Papamargaritis,Vanita R Aroda et al.
Kamlesh Khunti et al.
Controlling weight and cardiovascular risk factors is paramount in type 2 diabetes management; however, the definition and feasibility of remission warrant closer examination. Type 2 diabetes remission, typically attained through weight los...
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice [0.03%]
多发性内分泌腺瘤病1型(MEN1)最佳诊疗实践的建议和指南
Maria Luisa Brandi,Carolina R C Pieterman,Katherine A English et al.
Maria Luisa Brandi et al.
Multiple endocrine neoplasia type 1 (MEN1) is characterised by combined occurrence of parathyroid tumours, duodenopancreatic neuroendocrine tumours, and anterior pituitary adenomas. Some patients might also develop thymic and bronchopulmona...
Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis [0.03%]
神经内分泌肿瘤的治疗方法：三项系统评价和一项荟萃分析
Katherine A English,Carolina R C Pieterman,Francesca Marini et al.
Katherine A English et al.
Background: Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary disorder characterised by the combined occurrence of parathyroid, pancreatic, and pituitary tumours. Current treatments are based on very low-qua...